ArticleCurrent drug delivery2026
Formulation and Evaluation of Capecitabine-Loaded Microsponges for Colon Targeting.
Article in Current drug delivery, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
introductionCapecitabine (CAP) is a chemotherapeutic drug used via oral administration for the management of metastatic cancers of the breast and colon. CAP is a prodrug of 5-fluorouracil, which inhibits DNA synthesis and slows tumor growth. The objective of the current research was to develop colon-targeting CAP-loaded microsponges by quasi-emulsion solvent diffusion technique employing Hydroxypropyl Cellulose (HPC) and Ethyl Cellulose (EC) as constituent polymers at different ratios with varying stirring speeds (rpm).
methodsIn the present study, CAP-loaded microsponges were formulated by quasi-emulsion solvent diffusion method using HPC and EC as polymers at different ratios with varying stirring speeds. The 32-factorial design was used to perform the statistical optimization of CAP-loaded microsponges. The in vivo pharmacokinetic study of the optimized formulation of CAP-loaded microsponges was performed using Albino Wistar Rats.
resultsBased on the statistical optimization, the F1 formulation prepared using a 7:1 ratio of HPC and EC with 1000 rpm stirring speed was selected for its effective drug release (31.13 ± 1.73% after 8 hours and 69.57 ± 2.53% after 12 hours) and the highest drug entrapment efficiency (73.09 ± 3.54%). The 1.28-fold increase in AUC DISCUSSION: These findings indicated the potential delivery of CAP by these CAP-loaded microsponges to the colon, enabling sustained delivery and improving the bioavailability of CAP. However, comparative evaluation with existing marketed formulation and stability studies is essential to validate its therapeutic implications.
conclusionThe developed CAP-loaded microsponges could serve as an effective carrier for the sustained release of CAP, thereby improving the oral bioavailability of CAP for the management of colon cancer.
Indexed as
Identifiers
40798969What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.